Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Japanese firms boost U.S. R&D
March 6, 2006
| A version of this story appeared in
Volume 84, Issue 10
The U.S. subsidiary of Japanese drugmaker Eisai plans to invest $105 million to build a pharmaceutical production and formulation R&D facility at its existing site in Research Triangle Park, N.C. The new facility, which is set to open in 2009, will be dedicated to developing intravenous cancer drugs. The company expects the addition to bring 84 new jobs to the site over the next five years. Separately, Tokyo-based Astellas Pharma has bought Dynogen Pharmaceuticals' North Carolina-based research facility specializing in preclinical studies for genitourinary disorders.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter